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Abstract
Background: To study the effect of an ab interno gelatin stent (XEN45 Gel Stent, Allergan Inc., Irvine, California,
USA) on intraocular pressure (IOP) as placed by glaucoma fellowship trainees in eyes with refractory glaucoma.
Methods: A prospective noncomparative study at a tertiary training center on 28 unique eyes undergoing ab
interno gelatin stent implantation by glaucoma fellowship trainees. Data was collected at baseline and postoperatively
at day 1, week 1, and months 1, 3, 5, and 12. Primary outcome was mean IOP change. Secondary outcomes included
change in number of glaucoma medication classes and visual acuity. Safety outcomes included needling rates. Surgical
success was defined by achieving ≥20% reduction in IOP with the same or fewer classes of antiglaucoma medications
from baseline without the need for secondary surgical intervention and/or stent removal.
Results: At baseline, 28.6% (8/28) of the subjects had prior failed incisional glaucoma surgery in a study population
that was 54% African-American, with 78% with severe glaucoma (average mean deviation of − 14.58 dB). Thirteen
subjects terminated their clinic visits before their 12-month postoperative visit, leaving 15 subjects for end point
analysis. Average IOP went from 21.6 mmHg (range 12.0–31.0, SD 6.6) at baseline to 12.5 mmHg (range 7.0–19.0, SD
3.6), a 42.1% reduction (p < 0.007). All subjects decreased the number of medication classes they were taking with an
average reduction of 3.8 (range 2–5, SD 0.9) to 1.3 (range 0–3, SD 1.0) classes, or a 65.8% decrease (p < 0.006). Crude
surgical success was 80.0% for the 15 subjects that followed up at 12 months. The Kaplan-Meier cumulative probability
of success for all 28 subjects at 12 months was 70.4% (95% CI: 44.7–85.8%). Regardless of the length of follow-up, 21.4%
(6/28) met failure criteria: 3 subjects failed because they required secondary surgical intervention, and the other 3 did
not have adequate IOP reduction. Initial bleb needling rate was 28.6% (8/28) and repeat was 17.9% (5/28).
Conclusions: Compared to the reported literature with experienced ocular surgeons, ab interno gel stent placements
by glaucoma fellowship trainees have similar mean IOP, topical medication reduction, surgical success, and needling
rates at 12-month follow-up.
Keywords: XEN, Investigational devices, Glaucoma, Gelatin stent, Ab interno surgery, Minimally invasive glaucoma
surgery, Subconjunctival drainage, Gelatin microstent
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Background
Glaucoma is the leading cause of irreversible blindness
worldwide, currently affecting 64 million people globally
and projected to impact 112 million by 2040 [1]. In primary
open angle glaucoma (POAG), which accounts for approximately 70% of all glaucoma [1], the abnormal resistance is
believed to be located along the outer aspect of the trabecular meshwork, which is the drainage system of the eye. The
resistance to flow causes the intraocular pressure (IOP) to
increase, which can result in damage to the optic nerve that
can cause blindness. Therefore, the cornerstone of glaucoma treatment consists of IOP reducing medications,
devices, and surgery, introduced in a step-wise fashion.
The treatment of glaucoma is approached in a stepwise fashion. Medication often is the initial treatment of
choice aimed at lowering the IOP. If medication fails to
adequately reduce the pressure or there are challenges
to access and/or compliance, selective laser trabeculoplasty (SLT) may be performed. The drawback of SLT is
that its effectiveness generally decreases over time [2].
If these conservative therapies fail, incisional surgeries such as trabeculectomies and aqueous tube shunts
are considered. In a trabeculectomy, a flap is created
over a hole that allows fluid inside the eye to drain
beneath the conjunctiva. Aqueous shunt devices drain
aqueous fluid through a silicone tube to the outer
surface of the eye. These procedures are superior to
medications at lowering IOP, but both are not known
to be long lasting and can have devastating complications and failures. Reoperation may be needed for
scarring that prevents the new filtration track from
draining. One study showed a 40% failure rate 6 years
after trabeculectomy [3], even with the administration
of mitomycin C (MMC), an agent applied at the time
of surgery to prevent scarring. Significant diplopia can
occur if the aqueous shunt plate is placed too close
to an ocular muscle. Due to the poor ability to control pressure fluctuations with these surgeries, both
procedures carry a risk of blebitis, endophthalmitis, or
choroidal hemorrhage.
Micro-invasive glaucoma surgery (MIGS) may have
better safety profiles compared to traditional incisional
glaucoma surgeries. The surgery minimizes conjunctival
trauma and are usually placed under direct visualization
of anterior chamber angle anatomy. Most MIGS use a
clear corneal incision, known as an ab interno approach,
to allow drainage of fluid through 1 of 4 pathways: 1)
bypassing the trabecular meshwork, 2) increasing
uveoscleral outflow through suprachoroidal pathways, 3)
decreasing ciliary body aqueous or 4) creating a subconjunctival drainage pathway. Avoiding damage to the conjunctiva also allows the possibility of future glaucoma
surgery. MIGS procedures are typically performed on
patients with mild to moderate glaucoma because the
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amount of IOP reduction is not as great as traditional
incisional approaches.
The XEN45 Gel Stent (Allergan Inc., Irvine, CA, USA)
is a United States Food and Drug Administration
(FDA)-approved device that drains excess fluid produced
within the eye through the subconjunctival drainage
pathway that bypasses trabecular and scleral resistance.
Currently, it is the only device that mimics the nonphysiologic drainage pathway of trabeculectomy and
aqueous shunt surgeries while obviating the need for
conjunctival dissection. The stent is comprised of a porcine gelatin crosslinked with glutaraldehyde that may be
better accepted by human tissue and potentially
minimize erosion. The gelatin also imparts hydrophilic
properties that allow the implant to expand when hydrated by aqueous contact, which may help secure the
device location after surgical implantation and prevent
stent migration.
Given its relatively recent appearance on the market
(FDA approval on November 21, 2016), the XEN45
MIGS procedure is not as commonly performed as incisional or other available MIGS procedures. The first prospective studies started with examination of the larger
XEN63 and XEN140 devices [4, 5] and since then there
have been prospective [6–11] and retrospective [12–15]
studies examining the safety and efficacy of XEN45 Gel
Stent placement. Overall, the consensus is that the
XEN45 is effective in lowering IOP in patients with open
angle glaucoma over the course of 12 months [16]. Complications are usually transient and mild to moderate in
severity, with transient hypotony being the most commonly noted adverse event [4, 6–8]. Fortunately, complications are rare, although a suprachoroidal hemorrhage
had been reported as a case study [17]. Stent failures
required secondary surgical intervention and/or explantation [5–9]. All studies reported averages of > 20%
reduction in IOP, and found needling to be a common
intervention for bleb management [5–10].
There is a paucity of data on success rates of XEN45
Gel Stent implantations performed by surgical trainees.
Marques et al. [18] published 1 study examining the first
6 gel stent implantations of 5 ophthalmology resident
physician trainees who had performed over 250 cataract
surgeries, compared to 5 experienced ophthalmic
specialist surgeons with no prior XEN45 placement experience trained by Allergan (Allergan Inc., Irvine,
California, USA). Both were found to have similar mean
surgical times, but residents had more intraoperative
and postoperative complications such as bleb hemorrhage,
XEN45 placement and drainage issues, hypotony, and
transitory inflammatory reactions. These complications
decreased over the course of the residents’ first through
sixth surgeries. The study did not compare pre- and postoperative IOP.
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To the best of our knowledge, safety and efficacy studies of the XEN45 have not been characterized in ophthalmology fellowship trainees. As ab interno gelatin
stent popularity increases, it will likely become a more
common procedure practiced by residents and fellows at
teaching institutions. Given the advantageous safety profile of MIGS compared to incisional surgeries, ophthalmic trainees should be familiar with a variety of MIGS
procedures to provide the full spectrum of surgical
options to their patients. The aim of this study is to
describe the success rate, failures, and complications of
the XEN45 stent placement as performed by glaucoma
fellowship trainees at a tertiary teaching hospital. Those
results will be compared to outcomes of experienced
ophthalmic surgeons, as described in the literature.

Methods
Design

This prospective study was approved by the Institutional
Review Board of the Washington University in St. Louis
Human Research Protection Office and was conducted
in accordance with tenets of the Declaration of Helsinki.
All patients were provided written informed consent that
was signed prior to enrollment into the study and received treatment in accordance with United States federal regulations. This study was compliant with the
Health Insurance Portability and Accountability Act.
Participants

Eligible subjects were identified from a pool of clinic patients 45 years and older who had refractory glaucoma
and were recruited from January 1, 2016 to December
31, 2018. Refractory glaucoma was defined as previously
failing a filtering or cilioablative procedure (e.g., cryotherapy, cyclodiode therapy), or subjects who had any
other glaucomas that did not provide satisfactory results
(including neovascular, congenital or infantile glaucomas) or IOP uncontrolled on maximum tolerated
medical therapy (defined as a minimum of 4 or more
classes of topical glaucoma medications or fewer if
others were not tolerated or were ineffective). Anatomically, subjects were required to have an area of healthy,
free and mobile conjunctiva in the target surgical quadrant, along with trabecular meshwork visible on gonioscopy, with Shaffer angle grade ≥ 3 in the target
quadrant. Best-corrected visual acuity (BCVA) had to be
light perception or better at their first preoperative visit.
Subjects were required to have presence of a detectable
glaucomatous field defect, defined as a mean deviation
score of ≤ − 3 dB based on a SITA Standard 24–2 visual
field analysis from a reliable, interpretable visual field
exam (for eyes with BCVA better than 20/100). For
BCVA of 20/100 or worse, no visual field eligibility criterion was required. Recruitment only occurred if the
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subject had the availability, willingness, and sufficient
cognitive awareness to comply with examination procedures and the required visit schedule.Exclusion criteria
were: angle closure glaucoma where the angle was not
surgically opened, active neovascular glaucoma, clinically
significant inflammation or infection, active uveitis, any
corneal disease, central corneal thickness ≤ 490 μm or ≥
620 μm, presence of vitreous in the anterior chamber,
presence of intraocular silicone oil, active retinal disease,
anticipated need for other ocular surgery in the 12
month follow-up period, fellow (non-study) eye with
BCVA worse than 20/200, inability to discontinue contact lens wear, impaired episcleral venous drainage, history of dermatologic keloid formation, steroid use within
the past 30 days that is not chronic, requiring anticoagulation therapy other than 81 mg aspirin a day at the time
of surgery, recent chemotherapy, known or suspected allergy or sensitivity to porcine products or glutaraldehyde, fellow eye with an attempted non-study
implantation procedure, concurrent participation in another drug or device clinical trial, and/or pregnant or
nursing women.
Surgical criteria

The XEN45 Gel Stent would not be implanted if any of
the following were observed prior to implantation: 1) A
lack of healthy conjunctiva showing free mobility (free of
scarring or evidence of prior surgery) in the targeted
quadrant. 2) Excessive intraoperative bleeding, such that
visualization in the eye was impaired. 3) Any anatomy or
finding in the eye that limited the investigator’s ability to
visualize the anterior chamber, angle, or targeted quadrant of the conjunctiva. 4) Other surgical complication
that in the opinion of the investigator could impede
proper placement of the implant. Subjects who failed to
meet the intraoperative eligibility criteria were converted
to a different glaucoma intervention (e.g., trabeculectomy) prior to placement of the XEN45 Gel Stent and
were exited from the study.
Gelatin stent

The XEN45 Gel Stent is a microscopic hydrophilic tube
composed of porcine dermis-derived gelatin, crosslinked
to glutaraldehyde. Its dry inner and outer diameters are
approximately 45 μm and 150 μm, respectively, with a
length of 6 mm. The device comes preloaded in the sterile XEN Injector (Allergan Inc., Irvine, California, USA)
for surgical placement of the stent. Details have been
previously published on this device [19].
Surgical technique

The XEN45 Gel Stent target quadrant area was injected
with mitomycin C (MMC; Mitosol; Mobius Therapeutics
LLC, St Louis, Missouri, USA). Needle cap and retention

Hong et al. Eye and Vision

(2020) 7:5

plug were removed from the top of the sterile preloaded
XEN Injector containing the implant. Using an ab
interno approach, the surgeon advanced the tip of the
needle through the peripheral cornea, just anterior to
the limbus, and across the anterior chamber to the target. Once the tip of the needle was aligned with the desired entry point into the trabecular meshwork, the
surgeon advanced the needle through the trabecular
meshwork and sclera. The surgeon was then able to directly visualize the entire beveled needle tip as it exits the
sclera into the subconjunctival space with the surgical
microscope. When the beveled tip of the needle reached
the subconjunctival space, the surgeon released the implant by moving the slider forward. Once the implantation procedure was complete, the surgeon removed and
discarded the injector. The participant took the following postoperative medications: fluoroquinolone (four
times a day, on week 1 following surgery) and prednisolone acetate 1% (four times a day for weeks 1–4; three
times a day on week 5; two times a day on week 6; every
day for weeks 7–12). The glaucoma fellows were ophthalmic surgeons who had graduated from ophthalmology residency and were undergoing glaucoma subspecialization under the mentorship of an accredited
glaucoma specialist. Trainees performed these surgeries
over the course of 1 year at Washington University in St.
Louis School of Medicine, in collaboration with BarnesJewish Hospital (St. Louis, Missouri, USA).
Assessments and outcomes

The preoperative visit included a routine complete ophthalmic history and examination with visual field testing.
The severity of glaucoma was classified as low, moderate, or severe based on visual field testing and the glaucoma definition in the 10th revision of the International
Statistical Classification of Diseases [20].
Postoperative visits occurred at day 1, weeks 1 (7 ± 2
days) and 2 (14 ± 3 days), and months 1 (28 ± 7 days), 3
(84 ± 14 days), 6 (182 ± 14 days), 8 (238 ± 14 days), 10
(294 ± 14 days), and 12 (375 ± 45 days). Postoperative
visits included a routine history and examination and
notation of any complications or needling procedures.
IOP measurements were made by Goldmann applanation tonometer. Best corrected visual acuity and the
number of anti-glaucomatous medications were recorded at all visits.
Statistical analysis

The primary outcome was the mean IOP change from
baseline to 12 months for all subjects who completed
their baseline and 12-month follow-up exam.
Secondary outcomes included changes in mean IOP
and mean number of antiglaucoma medications at 3,
6, and 12 months compared to baseline. Additional
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descriptors included BCVA, bleb needling rates, and
success of XEN45 Gel Stent intervention. Success was
defined as percentage of patients achieving ≥20%
mean diurnal IOP reduction by 12 months on the
same number or fewer antiglaucoma medications.
Safety outcomes included adverse events, glaucomarelated secondary surgical interventions, XEN45 explantations, and analysis of surgical failure.
One eye per subject was analyzed using STATA 14.2
(StataCorp LP, College Station, Texas, USA). If there
were 2 surgical eyes from the same subject, only the first
surgical eye was selected for analysis. Descriptive data
were presented as means and standard deviations, or
counts and percentages as appropriate. Wilcoxon
signed-rank tests were used to compare means between
quantitative variables with a p value of 0.05 or less considered statistically significant. For subjects with missing
values, the subject’s last clinic visit was designated as the
date of loss to follow-up. A Kaplan-Meier curve was
plotted to express cumulative survival, with a failure defined as a glaucoma-related secondary surgical intervention with or without device explantation, device
explantation alone, or not achieving ≥20% IOP reduction
on the same number of medications or fewer by 12
months, similar to previous studies [7].
Primary and secondary outcomes were analyzed with
subjects that had baseline and 12-month follow-up visits.
Safety outcomes were analyzed with all included subjects. Subjects with missing data were censored at date
of last follow-up for Kaplan-Meier survival analysis.

Results
Participants

There was a total of 28 patients (31 eyes) that were recruited in the study, with 3 eyes excluded because the
first surgical eye was already included from the same patient. Preoperative baseline eye measurements and characteristics are found in Table 1. All subjects were either
non-Hispanic White (46.0%) or African-American
(54.0%). Most subjects had primary open angle (60.7%),
juvenile open angle (14.3%), or normal-tension glaucoma
(10.7%) with the most common prior glaucoma surgery
being SLT. The majority of subjects had severe glaucoma (78.6%), defined as optic nerve findings consistent
with glaucomatous visual field abnormalities in both
hemifields and/or loss within 5 degrees of fixation in at
least one hemifield [20]. Subjects had an average mean
deviation on visual field testing of − 14.58 dB (SD 9.0 dB)
at baseline preoperatively. There were 6 subjects (21.4%)
that accounted for 8 prior failed incisional glaucoma surgeries (Table 1). One subject had a failed diode and 2
failed MIGS implantations (iStent and ExPRESS Mini
Glaucoma Shunt with mitomycin C), all in one eye. All
other subjects had one prior failed surgery each. There
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Table 1 Baseline Demographics and Characteristics
Demographic/Characteristic

n = 28 subjects

Mean Age, years (SD)

66.6 (11.0)

Female, n (%)

11 (39.3)

Ethnicity, n (%)
Non-Hispanic White

13 (46.0)

Black/African American

15 (54.0)

Type of glaucoma, n (%)

were no Gonioscopy-Assisted Transluminal Trabeculotomy or Dual Blade procedures performed on any of the
eyes.
Most of the surgeries (82.1%) were completed by 1 of
4 fellows with the attending surgeon in the operating
room, but 5 of the cases (17.9%) were completed by a
glaucoma fellow on their own, independent of supervision. Table 2 lists other intraoperative variations.
Table 1, see end of document text file.

Primary Open Angle

17 (60.7)

Juvenile Open Angle

4 (14.3)

Primary outcome

Normal Tension

3 (10.7)

Pseudoexfoliative

2 (7.1)

Uveitic

2 (7.1)

All primary outcome data were calculated with IOPs recorded at baseline and the 12-month postoperative visit
(n = 15 eyes). Preoperatively, patients had an average
IOP of 21.6 mmHg (range 12.0–31.0, SD 6.6) that was
reduced to 12.5 mmHg (range 7.0–19.0, SD 3.6) at 12
months postoperatively (p < 0.007). This was an average
IOP reduction of 42.1% from preoperative baselines, or
9.1 mmHg (range 1.0–23.0, SD 6.1) (Fig. 1).

Preoperative lens status, n (%)
phakic

20 (71.4)

pseudophakic

8 (28.6)

Total Prior Glaucoma Surgery, n (%)a

6 (21.4%)

Non-valved tube

2 (7.1)

ExPRESS shunt with MMC

2 (7.1)

Secondary outcomes

Ahmed

1 (3.6)

TM iStent

1 (3.6)

Trabeculectomy

1 (3.6)

Diode

1 (3.6)

The primary outcome of average IOP change was also analyzed at 3 and 6 months, as those postoperative visits had
more subjects completing the visits than at 12 months. At
3 months (n = 23) and 6 months (n = 19), there was an
average IOP reduction of 21.7%, or 6 mmHg (range − 3.0–
16.0, SD 5.2) and 35.0%, or 7.5 mmHg (− 3.0–20.0, SD 5.7),
respectively.
There was a 65.8% decrease in the number of medication classes used 12 months after the intervention

Goniotomy (GATT or KDB)

0 (0.0)

Total Prior Non-Glaucoma Ocular Procedures, n (%)
Laser Trabeculoplasty
Prior other non-phacoemulsification surgery

23 (82.1)
21 (75.0)

b

2 (7.1)

Glaucoma Severityc
Severe

22 (78.6)

Moderate

2 (7.14)

Mild

4 (14.3)

Mean Deviation, dB (SD)

−14.58 (9.0)

Mean preoperative IOP, mmHg (range, SD)

21.7 (5.6)

IOP range mmHg

12–34

Mean Glaucoma Medication Classesd, n (SD)

3.7 (0.8)

1 class

0 (0.0)

Table 2 Intraoperative Characteristicsa
Characteristic

n = 28 subjects

Operative eye (right eye), n (%)

14 (50.0)

Fellow-only procedureb

5 (17.9)

Combined phacoemulsification/XEN procedure, n (%)

9 (32.1)

MMC timing
Before

27 (96.4)

After

1 (3.6)

2 classes

2 (7.1)

3 classes

7 (25.0)

4 classes

16 (57.1)

0.2 mg/ml

27 (96.4)

5 classes

3 (10.7)

0.4 mg/ml

1 (3.6)

Mean MMC total administration, mcg (SD)

37.9 (1.7)

20 mcg

3 (10.7)

30 mcg

4 (14.3)

40 mcg

19 (67.9)

60 mcg

2 (7.1)

SD= standard deviation; MMC= mitomycin C; IOP= intraocular pressure;
GATT= gonioscopy-assisted transluminal trabeculotomy; KDB= Kahook
Dual Blade
a
One subject with 3 prior glaucoma surgeries: a non-valved tube, diode, and
ExPRESS shunt with MMC
b
IOL repositioning (n = 1), pars plana vitrectomy (n = 1)
c
Glaucoma severity is described as optic nerve abnormalities consistent with
glaucoma and the following categorization of glaucomatous visual field
abnormalities: Severe = both hemifields and/or loss within 5 degrees of
fixation in at least one hemifield, Moderate = glaucomatous visual field
abnormalities in one hemifield and not within 5 degrees of fixation, Mild =
no abnormalities or only present on short-wavelength automated perimetry
or frequency doubling perimetry
d
Oral carbonic anhydrase inhibitors are considered their own class

MMC concentration

a

All procedures were completed using an ab interno approach with closed
conjunctiva technique and injection of MMC. Air technique and Ophthalmic
Viscosurgical Device dissection were not used in any of the cases
b
Defined as a procedure performed by a glaucoma fellow without the
supervision of an attending glaucoma specialist
MMC= mitomycin C; SD= standard deviation
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Baseline

Day 1

Week 1

Month 1

Month 3

Month 6

Month 12

Time Since XEN Placement
All subjects with 1 year follow up (n=15)
Subjects with baseline IOP < 21 mmHg (n=7)
Subjects with baseline IOP 21 mmHg (n=8)

Fig. 1 Intraocular pressure (IOP) at baseline and after XEN placement. The solid line is the mean of all subjects (n = 15). The dotted and dashed
lines are subsets of the solid line, grouped by baseline IOP

compared to the preoperative numbers at baseline
(Fig. 2, n = 15). No medications were required for any
of the patients up to 1 month postoperatively. Subjects were using an average of 3.8 (range 2–5, SD 0.9)
medications classes prior to the operation and 1.3
classes (range 0–3, SD 1.0) 12 months later (p <
0.006). All subjects decreased the number of medication classes they were taking, and none increased at
any point during the study.
The magnitude of reduction in the number of medication classes from baseline was even greater at 3 and 6
months compared to 12 months. At 3 months (n = 23)
there was a 78.9% decrease in antiglaucoma medication
classes while at 6 months (n = 19) there was a 76.3%
decrease.
The mean BCVA was slightly improved by one line 12
months postoperatively from an average starting Snellen
chart vision of 20/40 to an ending average vision of 20/
30 (p < 0.0034, Fig. 3). As expected, the day after surgery,
there was an overall acute worsening of vision to an
average of 20/60 with gradual improvement back to
baseline or improvement from baseline visual acuity over
the course of 12 months. Half (14/28) of the subjects
had an improvement in visual acuity based on their last
known clinical visit. More than a quarter (8/28) maintained their baseline vision and a minority (6/28) had
worsened visual acuity. Of note, one subject who was
20/400 at baseline worsened to hand motion vision at
12 months.

The crude surgical success rate was 80.0% (12/15). All
3 subjects were considered surgical failures because they
did not have adequate IOP reduction at 12 months. The
subjects all initially had good IOP reductions after surgery, but one developed IOP < 20% reduction at 1 week,
and the other 2 subjects failed at 1 month. However, all
3 subjects still had IOPs lower at 12 months when compared to their preoperative baseline IOP measurement.
Upon accounting for censoring events, Fig. 4 shows
the cumulative probability of surgical success was 70.4%
(95% CI: 44.7–85.8%), as defined by achieving a 20% or
more reduction in IOP with the same or fewer classes of
antiglaucoma medications by 12 months, without the
need for secondary surgical intervention and/or stent removal. There were 13 patients that were censored: 7
subjects for a last known clinic visit occurring before
completing their 12-month postoperative visit and 6
subjects for returning to their referring provider once
stable prior to 1 year of follow-up as they could no longer make the study visits.
Surgical failures and adverse events

In total, there were 6 out of 28 subjects (21.4%) who
failed their XEN45 implantation surgeries. There were 3
eyes (10.7%) that required secondary surgical intervention (Table 3). One of these failures was in an eye with
moderate POAG with a malpositioned XEN Gel Stent 1
week postoperatively that developed into stent exposure
3 weeks later requiring device explantation and
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1

0
Baseline

Day 1

Week 1

Month 1

Month 3

Month 6

Month 12 Month 12+

Time Since XEN Placement
Red dot = median

Blue dot = outlier

Fig. 2 Number of glaucoma classes used by subjects at baseline and after XEN placement (n = 15). The interquartile range is from 25 to 75%, as
indicated by the respective upper and lower borders of the boxes. The adjacent limits are 1.5 times the upper and lower limits of the respective
interquartile ranges. Blue dots represent outliers. Red dots represent the median

Best Corrected Visual Acuity (logMAR)

1.5

1

.5

0
Baseline

Day 1

Week 1

Month 1

Month 3

Month 6

Month 12

Time Since XEN Placement
Fig. 3 Best Corrected Visual Acuity at baseline and after XEN placement (n = 15). Blue dots represent outliers. Red dots represent the median.
Interquartile range is from 25 to 75%, as indicated by the respective upper and lower borders of the boxes. The adjacent limits are 1.5 times the
upper and lower limits of the respective interquartile ranges. Blue dots represent outliers. Red dots represent the median
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1.0
0.9

Cumulative Survival

0.8
0.7
0.6
0.5
0.4
0.3
0.2
Total Surgical Failures = 6 subjects (21.4%)

0.1
0.0
0

60

120
180
240
Days From XEN Stent Implantation

300

360

Fig. 4 Kaplan-Meier survival curve (n = 28). There were initially 28 subjects at the beginning of the study. Of those, 13 were censored for loss to
follow-up before 12 months. There were 6 subjects that were surgical failures

subsequent Molteno implantation. Another subject with
severe pseudoexfoliation glaucoma required preoperative
and postoperative needling procedures but continued to
have a slowly increasing IOP to 40 mmHg, ultimately requiring an Ahmed valve placement. The third subject
had severe juvenile open angle glaucoma with a prior
ExPRESS shunt (Alcon Laboratories Inc., Fort Worth,
TX) placement. Intraoperatively, this subject had a
curled XEN45 as opposed to the usual straight appearance of the device. This curved implant may indicate
that it is within tenon’s tissue instead of above the
tenon’s which is our center’s desired implant location.
The subject underwent a repeat XEN45 Gel Stent surgery after the first failed. The second XEN surgery was
not included in the analysis. There were no surgical failures the day of surgery and there have been no other
secondary surgical interventions or XEN explantations
beyond one-year thus far.

Table 3 Surgical Outcomes Summary
Subjects, n (%)
Total failure rate

6 (21.4)

Intraocular pressure not ≥20% reduction from baseline

3 (10.7)

Secondary surgical intervention

3 (10.7)

Postoperative Increase in antiglaucoma medications

0 (0.0)

Lost to follow-up prior to postoperative month 12a

13 (46.4)

a

Patients lost to follow-up were censored in survival analysis

Table 4 describes the adverse events that occurred in
the operating room and postoperative period. Trainees
had a median of 9 months of glaucoma training at the
time of implantation for the XEN45 devices that ultimately developed adverse events. Challenges intraoperatively were curled XEN Gel Stents (n = 3), a small orbit
(n = 1), and a scarred superior conjunctiva (n = 1). These
did not contribute to surgical failures other than the
curled XEN45 described previously. Of note, there were
5 fellow-only cases total, and none of them had
complications.
Postoperative interventions

There was 1 patient who required primary needling (day
of surgery). The rate of postoperative bleb needling increased until 3 months postoperatively when the most
needling and reneedling-procedures occurred (Table 5).
The total rate of first-time needling was 28.6%. The rate
of second time needling in the same patient was 17.9%.

Discussion
Traditional glaucoma surgery is currently not standardized and is invasive. The placement of the XEN45 Gel
Stent involves a novel minimally invasive surgery allowing for a more standardized approach to lowering intraocular IOP because the device length and inner lumen
are fixed. Its foremost advantage is placement without a
large conjunctival incision like those required in traditional glaucoma surgeries. Here we report the device
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Table 4 Adverse events of XEN stent implanta
Adverse eventb

Months in Fellowship Training
at XEN placement

Initial Procedure

Intraoperative
microhyphema

8

XEN

subconjunctival hemorrhage

5

XEN

Anterior chamber tap for OVD removal

9

XEN-phacoemulsification

Descemet’s blockage at tube lumen

11

XEN-phacoemulsification

Postoperative Day 1

Postoperative Week 1
Mild choroidal effusions

9

XEN

Serous choroidals

1

XEN

Low choroidals

9

XEN-phacoemulsification

Malpositioned XEN against iris

9

XEN

Malpositioned XEN pointing superiorly

11

XEN

11

XEN

Postoperative Month 1
XEN Exposure
a

All surgeries were performed with a supervising glaucoma attending
b
All listed events were unique incidences that occurred one time. There were no noted adverse events on postoperative month 3, month 6, or month 12
OVD= ophthalmic viscoelastic device

results when the surgery was performed by glaucoma
fellowship trainees, which would inform the device’s potential in the hands of ophthalmic surgeons early in their
surgical experience. Our results indicated a clinically significant 42.1% decrease in IOP from 21.6 mmHg to 12.5
mmHg, with a 65.8% reduction in medications in 15 eyes
with follow-up at 1 year, suggesting that the XEN45 is a
viable option for the surgical treatment of open angle
glaucoma.
Subjects’ best corrected visual acuity remained at baseline on average. However, since these results are only
over 12 months follow-up and correspond to 15 patients,
this may be too short a period to observe vision changes.
Out of the 15 patients who had follow-up at 12
months, there was a crude 80.0% (12/15) surgical
success rate which was higher than the cumulative

probability found by Kaplan-Meier analysis (70.4%).
This is likely because the survival curve examined all
28 subjects instead of only the 15 that had 12month postoperative visits, allowing 3 additional surgical failures to be accounted for through censoring
instead of being described as missing data like in the
crude calculation.
There were 6 total surgical failures out of 28 subjects,
3 requiring secondary surgical intervention and the
other 3 developing IOPs 20% over their baseline measurement. Adverse events included choroidal effusions
(self-limited, serous, and low) and XEN malpositioning.
These events centered around the first week and onemonth postoperative visits. Needling procedures
occurred the most during the third month postoperative
visit. Overall, over a fourth of subjects required needling

Table 5 Interventional bleb needling rates over time
Time
Postoperatively

First bleb
needling n (%)

Median MMC concentration
for initial needling (mcg)

Repeat
Needling
n (%)

Median MMC concentration
for repeat needling (mcg)

Needling
Complications (n)

Day of Surgery

1 (3.6)

60

0 (0.0)

–

Thick tissue (1)

Day 1

1 (3.6)

0

0 (0.0)

–

–

Week 1

1 (3.6)

0

0 (0.0)

–

–

Month 1

2 (7.1)

20

0 (0.0)

–

–

Month 3

2 (7.1)

10

3 (10.7)

20

Fractured XEN (1)

Month 6

1 (3.6)

5

1 (3.6)

20

Fractured XEN (1)

Month 12

0 (0.0)

0

0 (0.0)

–

–

Month 12+

0 (0.0)

0

1 (3.6)

0

–

MMC= mitomycin C
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postoperatively and roughly 1 in 5 subjects required
reneedling, making it common after XEN45 placement.
Despite the small sample size, additional analyses at 3
and 6 months where follow-up retention were consistent
with the final 12-month follow-up findings. IOP reduction and glaucoma medication reduction were significant
changes from the subjects’ preoperative baseline, indicating the feasible clinical application of the XEN45 device.
Comparison to the literature

There have been several noncomparative prospective
and retrospective studies [6–15] with consistent studyto-study trends even though the ranges for those effects
varied broadly. In general, subjects’ IOPs started at a
baseline in the low 20s and decreased to the low and
mid-teens by the end of the first year from XEN45 Gel
Stent placement. This was similar to our study’s finding.
The studies had an antiglaucoma medication class
reduction range from 51.4 to 94.6% [4–10]. The trainees
in our study had a 65.8% decrease in the number of classes for the 15 patients with 12-month follow-up, which
fell within the range of what was previously reported.
This suggests that outcomes are similar among trainees
compared to reported outcomes of experienced
surgeons.
Best corrected visual acuity outcomes were varied.
Galal et al. [8] saw a two-line improvement with subjects, but part of this improvement may be due to the
fact that over 30% of patients underwent the procedure
in combination with cataract surgery. Other studies saw
no statistically significant difference pre- and postoperatively [11], similar to our own findings.
Prior studies report a range of needling rates between
21.0–51.3% [4, 5, 7–9, 11, 12, 14, 15], with one reporting
2.4% [6]. Only 3 of the studies [4, 5, 15] mentioned that
they used MMC or 5-fluorouracil during needling. This
study’s postsurgical needling rate of 28.6% is within the
range of the reported literature, but lower than most of
the studies. The lower needling rate may be due to the
amount of MMC administered at the time of surgery,
but this is difficult to compare when the used concentrations vary per subject and study.
Despite the high preoperative glaucoma surgery failure
rate of 21.4% among the participants, XEN45 placement
as performed by trainees did not result in outcomes that
differ greatly from experienced surgeons. Studies looking
at surgical success rates ranged between approximately
60–80% [7–9, 12]. Our rate may have been on the higher
end compared to the literature because the patients that
did well likely continued returning to follow-up visits
due to care satisfaction. Postoperative dosing of MMC
may have also improved the overall success rate, as most
prior studies either did not perform repeat dosing of
MMC [8] or did not mention if it was administered
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concurrent with needling [6, 9, 11, 12, 14, 21]. Patients
lost to follow-up were censored in the survival analysis
since their outcome was unknown.
The results of our study conducted with glaucoma fellow trainees are consistent with the current reported literature of XEN45 Gel Stent outcomes as performed by
experienced ophthalmic surgeons in terms of IOP,
BCVA, and survival outcomes. It is notable that our outcomes were on a patient population with severe refractory glaucoma, suggesting that trainees can have good
outcomes even when operating on advanced disease.
Limitations

There were limitations to this study. First, this is a noncomparative study describing patient outcomes based on
multiple different glaucoma fellows. A glaucoma specialist comparison group to the trainee glaucoma surgeons
at the same institution may be able to elucidate subtle
outcome changes between experienced and nonexperienced surgeons.
Second, the large loss to follow-up of 13 patients in an
already small sample size may over or underestimate our
surgical success. The small sample size can cause large
changes in estimates with each subject that was lost to
follow-up. However, analysis at 3 months and 6 months
had only 5 and 9 missing subject measurements, respectively, and both time points had decreased IOP and less antiglaucoma medication classes used, similar to the findings at
12 months. Of note, the percentage of IOP reduction increased from 3 to 6 to 12 months. Subjects with better outcomes may have been more inclined to follow-up for
longer, leading to this result. Alternatively, the XEN45 may
have become more effective over time, or the additional interventions of needling and reintroduction of antiglaucoma
medications may have improved IOP control by 12 months.
The reduction in antiglaucoma medications was greater at
3 and 6 months compared to 12 months, which could be
due to the need for more antiglaucoma medications over
time. Regardless, it is supportive that the reduction in need
for antiglaucoma medications at 12 months is accurate, despite the small sample size. Even though the 3- and 6-month
data were not primary end points, it supported the 12month findings. Following outcomes beyond 12 months
could elucidate whether subjects go back to their baseline
medication class requirements over time.
Third, 7 of the subjects had concurrent phacoemulsification surgery, which makes it difficult to determine if
their measured outcomes were due to the XEN45 Gel
Stent, or removal of the cataract.

Conclusion
The literature suggest that implantation of the XEN45
Gel Stent by an experienced surgeon is effective in lowering IOP in open angle glaucoma patients with
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infrequent adverse events that are almost always mild in
severity and transient. Our results indicate that XEN45
Gel Stents can be implanted by a glaucoma trainee early
in their surgical career with good success in reducing
IOP by ≥20% at 12 months with similar outcomes and
adverse events to experienced surgeons, even when
treating severe glaucoma. Trainees should be proficient
at bleb management postoperatively because needling
interventions are commonly required after XEN45 Gel
Stent placement.
The main concern with incorporating the XEN45 Gel
Stent into the workflow of every glaucoma practice is
that the long-term safety and efficacy of the device is still
unknown. It is optimistic that early 12-month postoperative results demonstrate that the device is safe and effective in lowering both IOP and the number of
antiglaucoma medications, with a high surgical success
rate. Further studies looking at outcomes beyond 12
months would help determine the duration of these effects. Our results confirm the outcomes found in previous prospective noncomparative studies, and further
suggest that the XEN45 Gel Stent implantation safety
and efficacy features can be replicated even with young
surgeon trainees.
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